Cargando…

Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature

INTRODUCTION: The availability of raltegravir plus atazanavir provides an alternative antiretroviral strategy that may be equally efficacious and less toxic than those currently recommended in HIV treatment guidelines. In fact, this new combination antiretroviral therapy attracts the attention of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Ceccarelli, Giancarlo, d'Ettorre, Gabriella, Marchetti, Francesco, Rizza, Cecilia, Mastroianni, Claudio M, Carlesimo, Bruno, Vullo, Vincenzo
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3047431/
https://www.ncbi.nlm.nih.gov/pubmed/21329500
http://dx.doi.org/10.1186/1752-1947-5-70
_version_ 1782199037833773056
author Ceccarelli, Giancarlo
d'Ettorre, Gabriella
Marchetti, Francesco
Rizza, Cecilia
Mastroianni, Claudio M
Carlesimo, Bruno
Vullo, Vincenzo
author_facet Ceccarelli, Giancarlo
d'Ettorre, Gabriella
Marchetti, Francesco
Rizza, Cecilia
Mastroianni, Claudio M
Carlesimo, Bruno
Vullo, Vincenzo
author_sort Ceccarelli, Giancarlo
collection PubMed
description INTRODUCTION: The availability of raltegravir plus atazanavir provides an alternative antiretroviral strategy that may be equally efficacious and less toxic than those currently recommended in HIV treatment guidelines. In fact, this new combination antiretroviral therapy attracts the attention of the scientific community because both drugs have a good safety profile coupled with potent antiviral activity, and their combined use would avert nucleoside- and ritonavir-related toxicities. CASE PRESENTATION: We describe the case of a 47-year-old, Caucasian woman treated for HIV-1 infection who developed Buffalo Hump during antiretroviral therapy, including raltegravir and unboosted atazanavir. Clinical evaluation and an ultrasonography scan of the cervical region showed a new progressive increase of lipohypertrophy and the results of DEXA confirmed these data. In our patient the worsening of the Buffalo Hump cannot be attributed to hypercortisolism; insulin-resistance, diabetes, dyslipidemia, hyperlactatemia and metabolic syndrome were not present. Moreover, she was not in therapy with antiretroviral drugs that are described as the cause of Buffalo Hump; on the other hand she developed this side effect three months after the switch of the antiretroviral therapy to raltegravir plus unboosted atazanavir. CONCLUSION: Current data indicate that the etiology of HIV-associated Buffalo Hump remains elusive but is likely multifactorial; a possible contributing cause, but not the main cause, could be exposure to antiretroviral drugs. To the best of our knowledge, this is the first report on development of Buffalo Hump in the course of antiretroviral therapy, including the use of these drugs. On the basis of our data we can formulate the hypothesis of a pharmacological pathogenesis that underlies the development of this case of Buffalo Hump in the absence of other risk factors.
format Text
id pubmed-3047431
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30474312011-03-03 Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature Ceccarelli, Giancarlo d'Ettorre, Gabriella Marchetti, Francesco Rizza, Cecilia Mastroianni, Claudio M Carlesimo, Bruno Vullo, Vincenzo J Med Case Reports Case Report INTRODUCTION: The availability of raltegravir plus atazanavir provides an alternative antiretroviral strategy that may be equally efficacious and less toxic than those currently recommended in HIV treatment guidelines. In fact, this new combination antiretroviral therapy attracts the attention of the scientific community because both drugs have a good safety profile coupled with potent antiviral activity, and their combined use would avert nucleoside- and ritonavir-related toxicities. CASE PRESENTATION: We describe the case of a 47-year-old, Caucasian woman treated for HIV-1 infection who developed Buffalo Hump during antiretroviral therapy, including raltegravir and unboosted atazanavir. Clinical evaluation and an ultrasonography scan of the cervical region showed a new progressive increase of lipohypertrophy and the results of DEXA confirmed these data. In our patient the worsening of the Buffalo Hump cannot be attributed to hypercortisolism; insulin-resistance, diabetes, dyslipidemia, hyperlactatemia and metabolic syndrome were not present. Moreover, she was not in therapy with antiretroviral drugs that are described as the cause of Buffalo Hump; on the other hand she developed this side effect three months after the switch of the antiretroviral therapy to raltegravir plus unboosted atazanavir. CONCLUSION: Current data indicate that the etiology of HIV-associated Buffalo Hump remains elusive but is likely multifactorial; a possible contributing cause, but not the main cause, could be exposure to antiretroviral drugs. To the best of our knowledge, this is the first report on development of Buffalo Hump in the course of antiretroviral therapy, including the use of these drugs. On the basis of our data we can formulate the hypothesis of a pharmacological pathogenesis that underlies the development of this case of Buffalo Hump in the absence of other risk factors. BioMed Central 2011-02-17 /pmc/articles/PMC3047431/ /pubmed/21329500 http://dx.doi.org/10.1186/1752-1947-5-70 Text en Copyright ©2011 Ceccarelli et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Ceccarelli, Giancarlo
d'Ettorre, Gabriella
Marchetti, Francesco
Rizza, Cecilia
Mastroianni, Claudio M
Carlesimo, Bruno
Vullo, Vincenzo
Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature
title Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature
title_full Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature
title_fullStr Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature
title_full_unstemmed Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature
title_short Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature
title_sort development of buffalo hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3047431/
https://www.ncbi.nlm.nih.gov/pubmed/21329500
http://dx.doi.org/10.1186/1752-1947-5-70
work_keys_str_mv AT ceccarelligiancarlo developmentofbuffalohumpinthecourseofantiretroviraltherapyincludingraltegravirandunboostedatazanaviracasereportandreviewoftheliterature
AT dettorregabriella developmentofbuffalohumpinthecourseofantiretroviraltherapyincludingraltegravirandunboostedatazanaviracasereportandreviewoftheliterature
AT marchettifrancesco developmentofbuffalohumpinthecourseofantiretroviraltherapyincludingraltegravirandunboostedatazanaviracasereportandreviewoftheliterature
AT rizzacecilia developmentofbuffalohumpinthecourseofantiretroviraltherapyincludingraltegravirandunboostedatazanaviracasereportandreviewoftheliterature
AT mastroianniclaudiom developmentofbuffalohumpinthecourseofantiretroviraltherapyincludingraltegravirandunboostedatazanaviracasereportandreviewoftheliterature
AT carlesimobruno developmentofbuffalohumpinthecourseofantiretroviraltherapyincludingraltegravirandunboostedatazanaviracasereportandreviewoftheliterature
AT vullovincenzo developmentofbuffalohumpinthecourseofantiretroviraltherapyincludingraltegravirandunboostedatazanaviracasereportandreviewoftheliterature